Baroreflex Activation Therapy for the Treatment of Heart Failure With a ReducedEjection Fraction

JACC: Heart Failure

Volumn 3, Issue 6, 2015, Pages 487-496

  Abraham, William T ^a   Zile, Michael R ^b,c   Weaver, Fred A ^d   Butter, Christian ^e   Ducharme, Anique ^f   Halbach, Marcel ^g   Klug, Didier ^h   Lovett, Eric G ⁱ   Müller Ehmsen, Jochen ^j   Schafer, Jill E ^k   Senni, Michele ^l   Swarup, Vijay ^m   Wachter, Rolf ⁿ   Little, William C ^o  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e BRANDENBURG MEDICAL SCHOOL THEODOR FONTANE   (Germany)

^f MONTREAL HEART INSTITUTE   (Canada)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ CVRX INC   (United States)

^j ASKLEPIOS KLINIK ALTONA   (Germany)

^k NAMSA Inc   (United States)

^l PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^m Arizona Heart Hospital   (United States)

ⁿ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^o UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Autonomic nervous system; Baroreflex; Device; Heart failure; Randomized controlled trial

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; MINERALOCORTICOID ANTAGONIST;

6 MINUTE HALL WALK DISTANCE; ADRENERGIC SYSTEM; ADULT; ARTICLE; BAROREFLEX ACTIVATION THERAPY; BRADYCARDIA; CARDIAC IMPLANT; CARDIOVASCULAR DISEASE; CAROTID SINUS PRESSORECEPTOR REFLEX; CERVICAL NEURALGIA; CHOLINERGIC SYSTEM; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; EXERCISE TEST; FEMALE; FUNCTIONAL STATUS; HEART ATRIUM ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEMATOMA; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NEURALGIA; NEW YORK HEART ASSOCIATION CLASS; PHYSICAL CAPACITY; PNEUMOTHORAX; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; THERAPY; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE RETENTION; AGED; ELECTROTHERAPY; HEART STROKE VOLUME; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROSTHESIS IMPLANTATION;

AGED; BAROREFLEX; ELECTRIC STIMULATION THERAPY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSTHESIS IMPLANTATION; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84930870811     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.02.006     Document Type: Article

References (19)

1. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 2013, 128:e240-e327.
2. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
3. Floras J.S. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. JAm Coll Cardiol 2009, 54:375-385.
4. Ponikowski P., Anker S.D., Chua T.P., et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997, 79:1645-1650.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007. MERIT-HF Study Group.
6. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2817-2825.
7. Cohn J.N., Pfeffer M.A., Rouleau J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5:659-667.
8. Georgakopoulos D., Little W.C., Abraham W.T., Weaver F.A., Zile M.R. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. JCard Fail 2011, 17:167-178.
9. Hoppe U.C., Brandt M.C., Wachter R., et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. JAm Soc Hypertens 2012, 6:270-276.
10. Gronda E., Seravalle G., Brambilla G., et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014, 16:977-983.
11. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 1994, The Criteria Committee of the New York Heart Association, Little, Brown, Boston. 9th ed.
12. Rector R.S., Kubo S.H., Cohn J.N. Patients' self-assessment of their congestive heart failure. II. Content, reliability, and validity of a new measure-the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987, 3:198-209.
13. Guyatt G.H., Sullivan M.J., Thompson P.J., et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985, 132:919-923.
14. Madershahian N., Scherner M., Müller-Ehmsen J., et al. Baroreflex activation therapy in patients with pre-existing implantable cardioverter-defibrillator: compatible, complementary therapies. Europace 2014, 16:861-865.
15. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. NEngl J Med 2002, 346:1845-1853.
16. Fowler M.B. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?. Eur Heart J 1998, 19(Suppl P):P17-P25.
17. Pfister R., Diedrichs H., Schiedermair A., et al. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 2008, 10:315-320.
18. O'Connor C.M., Abraham W.T., Albert N.M., et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008, 156:662-673.
19. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. NEngl J Med 2014, 371:993-1004.